Boston Scientific Corporation has announced significant advancements in the use of artificial intelligence $(AI)$ to predict and prevent cardiac emergencies. Their AI technology is transforming healthcare by shifting from reactive to proactive and predictive medicine, enhancing the quality of care through early diagnoses and intervention. The company's HeartLogic™ Heart Failure Diagnostic, the first FDA-approved predictive analytic alert in an implantable device, is helping identify patients at risk for worsening heart failure weeks before symptoms appear. This innovative technology analyzes various physiological biomarkers, enabling the prediction of up to 70% of heart failure cases approximately 34 days in advance, thereby allowing physicians valuable time to intervene and potentially prevent emergencies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.